Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Beckman Coulter Life Sciences Acquires Blue Ocean Biomedical

By BiotechDaily International staff writers
Posted on 18 Apr 2012
Beckman Coulter Life Sciences (Indianapolis, IN, USA) has acquired Blue Ocean Biomedical, LLC (Pembroke Pines, FL, USA), manufacturer of automated flow cytometry systems and reagents. The transaction provides Beckman Coulter Life Sciences with low complexity analyzers that integrate automated sample preparation and directly address emerging flow cytometry-market trends.

Driving growth through internal product development and through acquisition of differentiated businesses and technologies is a core strategy for Beckman Coulter Life Sciences. The transaction expands the company’s flow cytometry line and targets routine clinical analyses. Blue Ocean Biomedical products complement the company’s existing cytometry portfolio with instruments based on a “sample in, result out” (SIRO) approach that represents a fundamental change in the routine clinical analysis sector.

“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president, Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”

Blue Ocean Biomedical products provide the first true integration of sample preparation, handling, analysis and data management, and the only SIRO solution for clinical flow cytometry, and will enable Beckman Coulter Life Sciences to deliver an expanding portfolio of clinical testing to a broader global market.

“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go’ flow cytometers,” said Mike Brochu, CEO and cofounder of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”

Related Links:
Beckman Coulter
Blue Ocean Biomedical




Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.